Active — Not RecruitingNot Applicable

A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.

Japan1,128 participantsStarted 2022-04-19

Plain-language summary

The purpose of this study is to learn about the safety and effectiveness (how well the study treatment works) of the study medicine (CIBINQO) for the potential treatment of atopic dermatitis in people under Japanese medical practice.

Who can participate

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Participants receiving this Product for treatment of AD.
✓. Participants start receiving this Product (commercial product) for the first time and no earlier than the contract date of this Study, or Participants who continues to receive this drug after hospital transfer can be registered retrospectively.

What they're measuring

Number of Participants with adverse drug reactions

Timeframe: 156 weeks

Number of Participants with Discontinuation of Treatment

Timeframe: 156 weeks

Trial details

NCT IDNCT05387980

SponsorPfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2028-11-01

View on ClinicalTrials.gov More Atopic Dermatitis trials